Association of GLP1-Receptor Agonist Use With Frailty and Falls in Adults With Type 2 Diabetes
- Design
- Retrospective cohort · 147184 participants · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants were veterans with type 2 diabetes; age and BMI are not reported in the abstract.
- Could weight loss explain it?
- PossiblyNo weight or HbA1c change or mediation analysis is reported; propensity matching addresses confounding, not mediation, so the frailty and falls association is presumed confounded with weight and glycaemic change.
- Study tier
- Study tier 3LOW: single retrospective new-user, active-comparator cohort; a single observational study is capped at LOW.
- Assessment
- Version 3 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
In US veterans with type 2 diabetes (main matched cohort of 73 592 pairs), starting a GLP-1 receptor agonist rather than a DPP-4 inhibitor was linked to slightly less worsening of frailty and fewer falls over a mean of about 27 months (fall rate ratio 0.87). The association was weaker in people who were already severely frail. This is an observational study, so it shows an association, not that the drugs prevented frailty or falls.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- dipeptidyl peptidase-4 inhibitors (active comparator)
- Primary outcome
- absolute change in Frailty Index from baseline to follow-up
- Effect
- GLP-1 receptor agonist initiation was linked to less frailty index worsening (regression coefficient -0.0010), lower odds of frailty index progression (OR 0.97) and a lower fall rate (IRR 0.87) than DPP-4 inhibitor initiation; estimates were attenuated in the severe-frailty cohort
- 95% confidence interval
- 95% CI: -0.0018 to -0.0002 (frailty index change)
- P value
- p = 0.011
- Follow-up
- mean approximately 27 months
- Adverse events
- not reported in abstract
- Limitations
- Observational propensity-matched as-treated cohort of veterans with diabetes, open to residual confounding; associations were small and attenuated in severe frailty.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes (Veterans Health data), at graded levels of baseline frailty
- Sample size
- 147184
- Inclusion exclusion
- adults with diabetes, 3 years of baseline data, new users with at least 90 days of therapy
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 147184
- Randomization
- no
- Blinding
- n/a
- Comparator
- dipeptidyl peptidase-4 inhibitors (active comparator)
- Follow up duration
- mean approximately 27 months
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI: -0.0018 to -0.0002 (frailty index change)
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] To evaluate the association of initiating glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors (as active comparator) with frailty progression and falls and whether associations differed by baseline frailty. [RESEARCH DESIGN AND METHODS] Five propensity score-matched retrospective cohorts using Veterans Health data (years 2006-2021), utilizing new-user, active-comparator design. The five matched cohorts were at progressive degrees of frailty at baseline and included adults with diabetes and 3 years of baseline data who initiated study medications with at least 90 days of therapy. [MAIN OUTCOMES AND MEASURES] Primary outcome was absolute change in Frailty Index from baseline to follow-up. Secondary outcomes were increase in the frailty index and fall rate during follow-up. Outcomes were assessed in an as-treated framework. [RESULTS] The main matched cohort included 73 592 pairs. Over a mean follow-up of approximately 27 months, glucagon-like peptide-1 receptor agonists initiation was associated with less worsening in frailty index (regression coefficient: -0.0010; 95% CI: -0.0018 to -0.0002; p = 0.011), lower odds of frailty index progression (OR: 0.97; 95% CI: 0.95-0.99; p = 0.003), and a lower fall rate (incidence rate ratio: 0.87; 95% CI: 0.84-0.91; p < 0.001) compared to dipeptidyl peptidase-4 inhibitor initiation. Findings were generally consistent across the other four matched cohorts, with attenuation in the matched cohort with severe frailty at baseline. [CONCLUSIONS] Initiation of glucagon-like peptide-1 receptor agonist was associated with slightly less frailty progression and fewer falls compared with dipeptidyl peptidase-4 inhibitor initiation, but estimates were attenuated in severe frailty.